Craig A. Tooman, MBA

Craig A. Tooman is President, Chief Executive Officer (CEO), and a board member of Silence Therapeutics plc (NASDAQ: SLN). Craig brings more than 30 years of operational, financial, and mergers and acquisitions (M&A) experience. Most recently, he was Chief Operating Officer and Chief Financial Officer (CFO) of Vyome Therapeutics, and prior to this, was CEO of Aratana Therapeutics, where he successfully negotiated a merger with Elanco. Before Aratana, Craig was CEO of Avanzar Medical Inc., a private oncology company, and CFO of Enzon Pharmaceuticals until its acquisition by Sigma Tau. Prior to that, he led the $1.1 billion M&A initiative and integration of ILEX Oncology and Genzyme Corporation. Craig also held key positions at Pharmacia and Upjohn. He holds a BA in economics from Kalamazoo College and an MBA from the University of Chicago.